Insider Trading Alert - MJN, JAZZ And CLB Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Feb. 14, 2014, 110 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $2,636.40 to $128,200,000.00.

Highlighted Stocks Traded by Insiders:

Mead Johnson Nutrition Company (MJN) - FREE Research Report

Golsby Stephen W who is Director at Mead Johnson Nutrition Company sold 10,000 shares at $77.78 on Feb. 14, 2014. Following this transaction, the Director owned 80,920 shares meaning that the stake was reduced by 11% with the 10,000-share transaction.

The shares most recently traded at $77.37, down $0.41, or 0.53% since the insider transaction. Historical insider transactions for Mead Johnson Nutrition Company go as follows:

  • 4-Week # shares bought: 500
  • 4-Week # shares sold: 10,000
  • 12-Week # shares bought: 500
  • 12-Week # shares sold: 30,000
  • 24-Week # shares bought: 500
  • 24-Week # shares sold: 60,525

The average volume for Mead Johnson Nutrition Company has been 1.7 million shares per day over the past 30 days. Mead Johnson Nutrition Company has a market cap of $15.7 billion and is part of the consumer goods sector and food & beverage industry. Shares are down 7.27% year-to-date as of the close of trading on Friday.

Mead Johnson is a subsidiary of Bristol-Myers Squibb Co., see separate record. The stock currently has a dividend yield of 1.75%. The company has a P/E ratio of 23.0. Currently there are 7 analysts that rate Mead Johnson Nutrition Company a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MJN - FREE

TheStreet Quant Ratings rates Mead Johnson Nutrition Company as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, expanding profit margins, increase in net income and notable return on equity. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Mead Johnson Nutrition Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 2,000 shares at $157.00 on Feb. 14, 2014. Following this transaction, the EVP and CFO owned 124,721 shares meaning that the stake was reduced by 1.58% with the 2,000-share transaction.

The shares most recently traded at $170.98, up $13.98, or 8.18% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 7,000
  • 24-Week # shares sold: 26,000

The average volume for Jazz Pharmaceuticals has been 862,100 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $9.3 billion and is part of the health care sector and drugs industry. Shares are up 26.5% year-to-date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 29.8. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Core Laboratories N.V (CLB) - FREE Research Report

Elvig Mark F who is VP, Counsel & Secretary at Core Laboratories N.V sold 1,500 shares at $186.64 on Feb. 14, 2014. Following this transaction, the VP, Counsel & Secretary owned 15,784 shares meaning that the stake was reduced by 8.68% with the 1,500-share transaction.

The shares most recently traded at $187.24, up $0.60, or 0.32% since the insider transaction. Historical insider transactions for Core Laboratories N.V go as follows:

  • 4-Week # shares sold: 1,500
  • 12-Week # shares sold: 1,500
  • 24-Week # shares sold: 7,204

The average volume for Core Laboratories N.V has been 240,100 shares per day over the past 30 days. Core Laboratories N.V has a market cap of $8.4 billion and is part of the basic materials sector and energy industry. Shares are down 2.26% year-to-date as of the close of trading on Friday.

Core Laboratories N.V. provides reservoir description, production enhancement, and reservoir management services to the oil and gas industry worldwide. The stock currently has a dividend yield of 1.07%. The company has a P/E ratio of 35.4. Currently there are 3 analysts that rate Core Laboratories N.V a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLB - FREE

TheStreet Quant Ratings rates Core Laboratories N.V as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, expanding profit margins, impressive record of earnings per share growth and increase in net income. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Core Laboratories N.V Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

null

More from Markets

Goldman to Continue I-Bank Dominance; Netflix Bonds Draw Attention - ICYMI

Goldman to Continue I-Bank Dominance; Netflix Bonds Draw Attention - ICYMI

Texas Instruments CEO Resigns After Violating Code of Conduct

Texas Instruments CEO Resigns After Violating Code of Conduct

Video: Here's How Goldman Sachs May Change Under David Solomon

Video: Here's How Goldman Sachs May Change Under David Solomon

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Abbott's Capital Flexibility in Focus Ahead of Earnings Release

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony

Markets Close Higher After Fed Chair Powell's Capitol Hill Testimony